The efficacy and safety of current treatments in diabetic macular edema: A systematic review and network meta-analysis

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Zhang, Lu ^a,b   Wang, Wen ^c   Gao, Yan ^b   Lan, Jie ^b   Xie, Lixin ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG EYE INSTITUTE   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; TRIAMCINOLONE; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ADVERSE OUTCOME; ANGINA PECTORIS; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE ABNORMALITY; LOW LEVEL LASER THERAPY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VISUAL ACUITY; DIABETIC RETINOPATHY; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; META ANALYSIS; NETWORK META-ANALYSIS; PATHOLOGY; PATIENT SAFETY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; LASER THERAPY; MACULAR EDEMA; NETWORK META-ANALYSIS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TRIAMCINOLONE; VISUAL ACUITY;

EID: 84979582247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159553     Document Type: Article

References (49)

1. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye. 2004 Oct; 18(10):963-83. PMID: 15232600
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984 Dec; 91(12):1464-74. PMID: 6521986
3. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Archives of ophthalmology. 1985 Dec; 103(12):1796-806. PMID: 2866759
4. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009 Jan; 116(1):73-9. doi: 10.1016/j.ophtha.2008.09.037 PMID: 19118698
5. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Experimental eye research. 1997 Apr; 64(4):505-17. PMID: 9227268
6. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). The American journal of pathology. 2000 May; 156(5):1733-9. PMID: 10793084
7. Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacological research. 2015 Sep; 99:137-48. doi: 10.1016/j.phrs.2015.05.013 PMID: 26054568
8. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Archives of ophthalmology. 1991 Nov; 109(11):1549-51. PMID: 1755735
9. Agarwal A, Afridi R, Hassan M, Sadiq MA, Sepah YJ, Do DV, et al. Novel Therapies in Development for Diabetic Macular Edema. Current diabetes reports. 2015 Oct; 15(10):75. doi: 10.1007/s11892-015-0652-z PMID: 26294336
10. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, Macugen Study G. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011 Jun; 118(6):1107-18. doi: 10.1016/j.ophtha.2011.02.045 PMID: 21529957
11. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013 Oct; 120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034 PMID: 23706949
12. Diabetic Retinopathy Clinical Research N, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007 Oct; 114(10):1860-7. PMID: 17698196
13. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014 Nov; 121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006 PMID: 25012934
14. Regnier SA, Larsen M, Bezlyak V, Allen F. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ open. 2015 Jun 5; 5(6):e007527. doi: 10.1136/bmjopen-2014-007527 PMID: 26048209
15. Das A, McGuire PG, Rangasamy S. Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology. 2015 Jul; 122(7):1375-94. doi: 10.1016/j.ophtha.2015.03.024 PMID: 25935789
16. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003 May; 44(5):2155-62. PMID: 12714656
17. Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Current drug targets. 2011 Feb; 12(2):173-81. PMID: 20887245
18. Kleijnen J, Korobelnik JF, Lang SH, Birnie R, Leadley RM, Misso K, et al. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmol. 2015 May 15; 15:52. doi: 10.1186/s12886-015-0035-x PMID: 25975823
19. Zhang XL, Chen J, Zhang RJ, Wang WJ, Zhou Q, Qin XY. Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis. Int J Ophthalmol. 2013 Aug 18; 6(4):546-52. doi: 10.3980/j.issn.2222-3959.2013.04.26 PMID: 23991395
20. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ open. 2013 Mar 1; 3(3).
21. Bhatnagar N, Lakshmi PV, Jeyashree K. Multiple treatment and indirect treatment comparisons: An overview of network meta-analysis. Perspectives in clinical research. 2014 Oct; 5(4):154-8. doi: 10.4103/2229-3485.140550 PMID: 25276624
22. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in medicine. 2002 Aug 30; 21(16):2313-24. PMID: 12210616
23. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of clinical epidemiology. 2011 Feb; 64(2):163-71. doi: 10.1016/j.jclinepi.2010.03.016 PMID: 20688472
24. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Statistical methods in medical research. 2008 Jun; 17(3):279-301. PMID: 17925316
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003 Sep 6; 327(7414):557-60. PMID: 12958120
26. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in medicine. 2010 Mar 30; 29(7-8):932-44. doi: 10.1002/sim.3767 PMID: 20213715
27. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England journal of medicine. 2015 Mar 26; 372(13):1193-203. doi: 10.1056/NEJMoa1414264 PMID: 25692915
28. Ishibashi T, Li X, Koh A, Lai TY, Lee FL, Lee WK, et al. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology. 2015 Jul; 122(7):1402-15. doi: 10.1016/j.ophtha.2015.02.006 PMID: 25983216
29. Berger A, Sheidow T, Cruess AF, Arbour JD, Courseau AS, De Takacsy F. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherpay in DME. Canadian Journal of Ophthalmology. 2015 Jun; 50(3):209-16. doi: 10.1016/j.jcjo.2014.12.014 PMID: 26040221
30. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014 Dec; 121(12):2473-81. doi: 10.1016/j.ophtha.2014.07.002 PMID: 25155371
31. Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American journal of ophthalmology. 2014 May; 157(5):960-70. doi: 10.1016/j.ajo.2014.02.019 PMID: 24531025
32. Shoeibi N, Ahmadieh H, Entezari M, Yaseri M. Intravitreal Bevacizumab with or without Triamcinolone for Refractory Diabetic Macular Edema: Long-term Results of a Clinical Trial. Journal of ophthalmic & vision research. 2013 Apr; 8(2):99-106.
33. Nepomuceno AB, Takaki E, Paes de Almeida FP, Peroni R, Cardillo JA, Siqueira RC, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American journal of ophthalmology. 2013 Sep; 156(3):502-10.e2. doi: 10.1016/j.ajo.2013.04.026 PMID: 23795985
34. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013 Sep; 120(9):1843-51. doi: 10.1016/j.ophtha.2013.02.018 PMID: 23706947
35. Berger A, Sheidow T, Li R, Rehel B, Takacsy F, Courseau AS. A canadian 12-month, phiiib study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("respond"). Canadian Journal of Diabetes [Internet]. 2013; 37:[S48 p.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/646/CN-01024646/frame.html, http://www.canadianjournalofdiabetes.com/article/S1499-2671(13)01088-5/pdf.
36. Arevalo JF, Lasave AF, Wu L, Diaz-Llopis M, Gallego-Pinazo R, Alezzandrini AA, et al. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months. Retina (Philadelphia, Pa). 2013 Feb; 33(2):403-13.
37. Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina (Philadelphia, Pa). 2012 Feb; 32(2):314-21.
38. Synek S, Veselý P. Intravitreal Bevacizumab with or without Triamcinolone for Refractory Diabetic Macular Oedema. Collegium antropologicum. 2011 Jul; 35(3):841-5. PMID: 22053565
39. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011 Apr; 118(4):615-25. doi: 10.1016/j.ophtha.2011.01.031 PMID: 21459215
40. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010 Nov; 117(11):2146-51. doi: 10.1016/j.ophtha.2010.08.016 PMID: 20855114
41. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010 Jun; 117(6):1078-1086.e2. doi: 10.1016/j.ophtha.2010.03.045 PMID: 20416952
42. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes care. 2010 Nov; 33(11):2399-405. doi: 10.2337/dc10-0493 PMID: 20980427
43. Diabetic Retinopathy Clinical Research N, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 Jun; 117(6):1064-1077.e35. doi: 10.1016/j.ophtha.2010.02.031 PMID: 20427088
44. Pappas GD, Adam CI, Papageorgioy E, Kefalogiannis N, Fanouriakis H. Triamcinolone and Grid Laser versus Bevacizumab Alone for the Treatment of Diabetic Macular Edema. Iovs [Internet]. 2008:[ARVO E- abstract 3483 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/124/CN-00746124/frame.html.
45. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2008 Apr; 246(4):483-9. PMID: 17917738
46. Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Liu DT, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology. 2007 Dec; 114(12):2162-7. PMID: 17459479
47. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta ophthalmologica Scandinavica. 2006 Oct; 84(5):624-30. PMID: 16965492
48. Dowler JG. Laser management of diabetic retinopathy. J R Soc Med. 2003 Jun; 96(6):277-9. PMID: 12782691
49. Kriechbaum K, Prager S, Mylonas G, Scholda C, Rainer G, Funk M, et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye. 2014 Jan; 28(1):9-15; quiz 16. doi: 10.1038/eye.2013.242 PMID: 24336297